Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bladder Disease Clear all
Completed Not applicable Interventional

Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection

NCT00303654
View directory record Official record
Conditions
Bladder Cancer
Interventions
biopsy, therapeutic conventional surgery
Procedure
Lead sponsor
Roei Medical Technologies Ltd.
Industry
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 17, 2026, 6:00 AM EDT
Completed Phase 2 Interventional

Oxaliplatin in Treating Patients With Metastatic Bladder Cancer

NCT00004203
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
oxaliplatin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
11
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 17, 2026, 6:00 AM EDT
Completed No phase listed Observational

A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers

NCT00779688
View directory record Official record
Conditions
Pancreatic Cancer, Bile Duct Cancer
Interventions
Probe-based confocal laser endomicroscopy
Device
Lead sponsor
Mauna Kea Technologies
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2011 · Synced Sep 17, 2026, 6:00 AM EDT
Completed Early Phase 1 Interventional

Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder

NCT05463822
View directory record Official record
Conditions
Overactive Bladder, Bladder, Overactive, Urge Incontinence, Urgency Urinary, Urinary Frequency/Urgency
Interventions
Transvaginal botulinum toxin A (BTA) injection
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 17, 2026, 6:00 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer

NCT00005086
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, docetaxel, gemcitabine hydrochloride, methotrexate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
4
States / cities
Chicago, Illinois • Peoria, Illinois • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 17, 2026, 6:00 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Stress and Anxiety Effects on Overactive Bladder

NCT05087810
View directory record Official record
Conditions
Overactive Bladder, Stress, Psychological, Anxiety
Interventions
Psychological stress induction, Accelerated oral hydration
Behavioral · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 17, 2026, 6:00 AM EDT
Completed No phase listed Observational

Fiber-Optic Confocal Microscopy of the Urinary Tract Histopathology

NCT00801762
View directory record Official record
Conditions
Bladder Cancer
Interventions
Fibered confocal microscope
Device
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 17, 2026, 6:00 AM EDT
Completed No phase listed Observational

A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy

NCT05179460
View directory record Official record
Conditions
Pigmentary Maculopathy, Pigmentary Retinopathy, Interstitial Cystitis
Interventions
Not listed
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 17, 2026, 6:00 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479
View directory record Official record
Conditions
Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions
LY4101174
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Orlando, Florida • Atlanta, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 6:00 AM EDT
Completed Phase 1 Interventional

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

NCT01004224
View directory record Official record
Conditions
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Squamous Lung Cancer With FGFR1 Amplification, Bladder Cancer With FGFR3 Mutation or Fusion, Advanced Solid Tumors With FGFR1 Amplication, Advanced Solid Tumors With FGFR2 Amplication, Advanced Solid Tumors With FGFR3 Mutation
Interventions
BGJ398
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 17, 2026, 6:00 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

NCT00995488
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer
Interventions
ABI-007 (Abraxane®)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Sep 17, 2026, 6:00 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

NCT05363605
View directory record Official record
Conditions
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer
Interventions
[225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 17, 2026, 6:00 AM EDT
Terminated No phase listed Observational

Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

NCT05819827
View directory record Official record
Conditions
Bladder Cancer, Prostate Cancer, Testicular Cancer, Bladder Carcinoma, Genitourinary System Carcinoma, Malignant Testicular Neoplasm, Melanoma, Prostate Carcinoma, Sarcoma
Interventions
Blood and Tissue
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 17, 2026, 6:00 AM EDT
Terminated Phase 1 Interventional Results available

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

NCT03125200
View directory record Official record
Conditions
Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions
ADCT-502
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Buffalo, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 17, 2026, 6:00 AM EDT
Completed Not applicable Interventional

Optimizing Overactive Bladder Treatment

NCT03904407
View directory record Official record
Conditions
Overactive Bladder
Interventions
Lactobacillus Probiotic Capsule, Matching Lactobacillus Probiotic Placebo Capsule
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Hillsborough, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 17, 2026, 6:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study

NCT04873271
View directory record Official record
Conditions
Overactive Bladder
Interventions
Medtronic Implantable Tibial Neuromodulation (TNM) System
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Marietta, Georgia • Englewood, New Jersey • Hamlet, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 17, 2026, 6:00 AM EDT
Recruiting Phase 1 Interventional

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

NCT05562791
View directory record Official record
Conditions
Bladder Cancer
Interventions
[68Ga]PSMA, PET/CT imaging
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 17, 2026, 6:00 AM EDT
Completed Not applicable Interventional Results available

FITBIT Study on Mobility and Readmissions After Radical Cystectomy

NCT04314778
View directory record Official record
Conditions
Bladder Cancer
Interventions
social incentive-based gamification
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 17, 2026, 6:00 AM EDT
Recruiting Phase 2 Interventional

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT06503146
View directory record Official record
Conditions
Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Ductal Adenocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Gastric Cancer, Cholangiocarcinoma, Bladder Cancer
Interventions
[18F]FAPI-74, [18F]FDG
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 17, 2026, 6:00 AM EDT
Not listed Phase 4 Interventional

Oral vs Intravesical Analgesia for Office Bladder Botox Injections

NCT03755089
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Detrusor Instability
Interventions
Phenazopyridine, Lidocaine 2% Injectable Solution
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Sep 17, 2026, 6:00 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT03633110
View directory record Official record
Conditions
Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma
Interventions
GEN-009 Adjuvanted Vaccine, Nivolumab, Pembrolizumab
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
La Jolla, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 17, 2026, 6:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants

NCT00900276
View directory record Official record
Conditions
Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
immunologic technique, laboratory biomarker analysis, mass spectrometry
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 17, 2026, 6:00 AM EDT
Terminated Not applicable Interventional Results available

Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

NCT02517996
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 17, 2026, 6:00 AM EDT
Completed Not applicable Interventional Results available

PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors

NCT01567462
View directory record Official record
Conditions
Bladder Cancer
Interventions
Monopolar electrocautery loop in Transurethral resection of bladder tumors, PK Button Vaporization Electrode in transurethral resection of bladder tumors
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 17, 2026, 6:00 AM EDT